Stockreport

enGene Holdings: Still A Buy After A Massive Surge [Seeking Alpha]

ImmunityBio, Inc.  (IBRX) 
PDF ENGN's phase 2 LEGEND trial showed a 63% complete response rate, comparable to ImmunityBio's Anktiva, positioning ENGN as a strong NMIBC contender. ENGN has a robust [Read more]